Autophagy: Novel action of panitumumab in colon cancer

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5077-5082

  Giannopoulou, Efstathia ^a   Antonacopoulou, Anna ^a   Matsouka, Panagiota ^a   Kalofonos, Haralabos P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Autophagy; Panitumumab; Redox status

Indexed keywords

BECLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE; PANITUMUMAB;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; ONCOGENE K RAS; OXIDATION REDUCTION STATE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA, NEOPLASM; GLUTATHIONE; HUMANS; IMMUNOBLOTTING; MUTATION; OXIDATION-REDUCTION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR CELLS, CULTURED;

EID: 75149165626     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Alekshun T and Garrett C: Targeted therapies in the treatment of colorectal cancers. Cancer Control 12: 105-110, 2005.
2. Giusti RM, Shastri KA, Cohen MH, Keegan P and Pazdur R: FDA Drug approval summary: panitumumab (Vectibix™). Oncologist 12: 577-583, 2007.
3. http://www.emea.europa.eu/humandocs/PDFs/EPAR/vectibix/H-741-PI-en.pdf, 1-28, 2009.
4. Amado RG, Wolf M, Peeters M, van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD and Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
5. Hecht JR: Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice. Am J Health Syst Pharm 65: S15-21, 2008.
6. van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, van Laethem JL, Maurel J, Richardson G, Wolf M and Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664, 2007.
7. Zhang W, Gordon M and Lenz HJ: Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med 38: 545-551, 2006.
8. Dutta PR and Maity A: Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 254: 165-177, 2007.
9. Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S and Corona G: Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers 22: S24-39, 2007.
10. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ and Hung MC: Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13: 385-393, 2008.
11. Yang XD, Jia XC, Corvalan JR, Wang P and Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38: 17-23, 2001.
12. Wu M, Rivkin A and Pham T: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther 30: 14-30, 2008.
13. Marmor MD, Skaria KB and Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903-913, 2004.
14. Raponi M, Winkler H and Dracopoli NC: KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 8: 413-418, 2008.
15. Ahn C, Jeong E, Lee J, Kim M, Kim SH, Kim SS, Yoo N and Lee S: Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers. APMIS 115: 1344-1349, 2007.
16. Cao Y and Klionsky D: Physiological functions of Atg6/beclin 1: a unique autophagy-related protein. Cell Res 17: 839-849, 2007.
17. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402: 672-676, 1999.
18. Blau S, Rubinstein A, Bass P, Singaram C and Kohen R: Differences in the reducing power along the rat GI tract: lower antioxidant capacity of the colon. Mol Cell Biochem 194: 185-191, 1999.
19. Rainis T, Maor I, Lanir A, Shnizer S and Lavy A: Enhanced oxidative stress and leucocyte activation in neoplastic tissues of the colon. Dig Dis Sci 52: 526-530, 2007.
20. Schumacker PT: Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10: 175-176, 2006.
21. Behrend L, Henderson G and Zwacka RM: Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 31: 1441-1444, 2003.
22. Valko M, Rhodes CJ, Moncol J, Izakovic M and Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160: 1-40, 2006.
23. Hwang C, Sinskey A and Lodish H: Oxidized redox state of glutathione in the endoplasmic reticulum. Science 57: 1496-1502, 1992.
24. Scibior D, Skrzycki M, Podsiad M and Czeczot H: Glutathione level and glutathione-dependent enzyme activities in blood serum of patients with gastrointestinal tract tumors. Clin Biochem 41: 852-858, 2008.
25. Giannopoulou E, Antonacopoulou A, Floratou K, Papavassiliou A and Kalofonos H: Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother Pharmacol 63: 973-981, 2009.
26. Calonghi N, Pagnotta E, Parolin C, Tognoli C, Boga C and Masotti L: 9-Hydroxystearic acid interferes with EGF signalling in a human colon adenocarcinoma. Biochem Biophys Res Comm 342: 585-588, 2006.
27. Giannopoulou E, Katsoris P, Parthymou A, Kardamakis D and Papadimitriou E: Amifostine protects blood vessels from the effects of ionizing radiation. Anticancer Res 22: 2821-2826, 2002.
28. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M,Tiniakos D, Tejpar S, Bevilacqua G and Ensari A: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453: 417-431, 2008.
29. Freeman D, Juan T, Reiner M, Hecht J, Meropol N, Berlin J, Mitchell E, Sarosi I, Radinsky R and Amado R: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7: 184-190, 2008.
30. Peeters M, Balfour J and Arnold D: Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol Ther 28: 269-281, 2008.
31. Plesec TP and Hunt JL: KRAS mutation testing in colorectal cancer. Adv Anat Pathol 16: 196-203, 2009.
32. Kuwada S, Scaife C, Kuang J, Li X, Wong R, Florell S, Coffey R Jr and Gray P: Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int J Cancer 109: 291-301, 2004.
33. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW and Hicklin DJ: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994-1003, 2002.
34. Mano M and Humblet Y: Drug insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. Nat Clin Pract Oncol 5: 415-425, 2008.
35. Jean G and Shah S: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 28: 742-754, 2008.
36. Vallböhmer D and Lenz H: Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer 5: S19-S27, 2005.
37. Spano JP, Fagard R, Soria JC, Rixe O, Khayat D and Milano G: Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 16: 189-194, 2005.
38. Emlet D, Schwartz R, Brown K, Pollice A, Smith C and Shackney S: HER2 expression as a potential marker for response to therapy targeted to the EGFR. Br J Cancer 94: 1144-1153, 2006.
39. Keller J, Franklin J, Graves-Deal R, Friedman D, Whitwell C and Coffey R: Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among Ras family members in the colonic epithelium. J Cell Physiol 210: 740-749, 2007.
40. Pal S and Pegram M: Epidermal growth factor receptor and signal transduction: potential target for anticancer therapy. Anticancer Drugs 16: 483-494, 2005.
41. INK4a. Cell 88: 593-602, 1997.
42. Russo A, Bazan V, Agnese V, Rodolico V and Gebbia N: Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 16: iv44-49, 2005.
43. Qadir M, Kwok B, Dragowska W, To K, Le D, Bally M and Gorski S: Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Treat 112: 389-403, 2008.
44. Ghezzi P: Regulation of protein function by glutathionylation. Free Radic Res 39: 573-580, 2005.
45. Aizawa S, Ookawa K, Kudo T, Asano J, Hayakari M and Tsuchida S: Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci 94: 886-893, 2003.